Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Arthritis Research & Therapy

Figure 4

From: Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis

Figure 4

Oral administration of STA-5326 during the effector phase reduces the severity of experimental autoimmune uveoretinitis (EAU) by clinical analysis. Clinical score of EAU in STA-5326-treated or vehicle-treated mice. Immunized mice were treated with 20 mg/kg STA-5326 or vehicle from day 9 to day 14 after immunization. Clinical findings were evaluated on day 15 and day 18 after immunization. Statistical analysis was performed by Mann-Whitney U test.

Back to article page